Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection

Journal of Clinical Investigation

Volumn 118, Issue 5, 2008, Pages 1776-1784

  Samuelsson, Christofer ^a   Hausmann, Jürgen ^a   Lauterbach, Henning ^a   Schmidt, Michaela ^a   Akira, Shizuo ^b   Wagner, Hermann ^c   Chaplin, Paul ^a   Suter, Mark ^a,d   O'Keeffe, Meredith ^a   Hochrein, Hubertus ^a  

^a Bavarian Nordic GmbH   (Germany)

^b OSAKA UNIVERSITY   (Japan)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MODIFIED VACCINIA VIRUS ANKARA VACCINE; TOLL LIKE RECEPTOR 9; VACCINIA VACCINE;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANARYPOX VIRUS; CELL MATURATION; CONTROLLED STUDY; COWPOX VIRUS; DENDRITIC CELL; ECTROMELIA VIRUS; IMMUNE RESPONSE; INFECTION SENSITIVITY; LEPORIPOXVIRUS; MOUSE; MOUSE POX; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SMALLPOX; VACCINATION; VACCINIA VIRUS; VIRUS ACTIVATION; VIRUS DETECTION; VIRUS INACTIVATION; VIRUS SURVIVAL;

ANIMALS; DENDRITIC CELLS; ECTROMELIA VIRUS; HUMANS; IMMUNITY; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; POXVIRIDAE INFECTIONS; SURVIVAL RATE; TOLL-LIKE RECEPTOR 9; VACCINATION; VACCINIA VIRUS;

EID: 43049088102     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI33940     Document Type: Article

References (32)

1. Fenner, F., Henderson, D.A., Arita, I., Jezek, Z., and Ladnyi, I.D. 1988. Smallpox and its eradication. WHO. Geneva, Switzerland. whqlibdoc.who.int/ smallpox/9241561106.pdf.
2. Esteban, D.J., and Buller, R.M. 2005. Ectromelia virus: the causative agent of mousepox. J. Gen. Virol. 86:2645-2659.
3. Seet, B.T., et al. 2003. Poxviruses and immune evasion. Annu. Rev. Immunol. 21:377-423.
4. Bowie, A., et al. 2000. A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling. Proc. Natl. Acad. Sci. U. S. A. 97:10162-10167.
5. Zhu, J., Martinez, J., Huang, X., and Yang, Y. 2007. Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-beta. Blood. 109:619-625.
6. Hemmi, H., et al. 2000. A Toll-like receptor recognizes bacterial DNA. Nature. 408:740-745.
7. Wagner, H., and Bauer, S. 2006. All is not Toll: new pathways in DNA recognition. J. Exp. Med. 203:265-268.
8. Hochrein, H., et al. 2004. Herpes simplex virus type-1 induces IFN-alpha production via Toll-like receptor 9-dependent and -independent pathways. Proc. Natl. Acad. Sci. U. S. A. 101:11416-11421.
9. Krug, A., et al. 2004. Herpes simplex virus type 1 activates murine natural interferon-producing cells through toll-like receptor 9. Blood. 103:1433-1437.
10. Delale, T., et al. 2005. MyD88-dependent and -independent murine cytomegalovirus sensing for IFN-alpha release and initiation of immune responses in vivo. J. Immunol. 175:6723-6732.
11. Tabeta, K., et al. 2004. Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc. Natl. Acad. Sci. U. S. A. 101:3516-3521.
12. Basner-Tschakarjan, E., et al. 2006. Adenovirus efficiently transduces plasmacytoid dendritic cells resulting in TLR9-dependent maturation and IFN-alpha production. J. Gene Med. 8:1300-1306.
13. Lund, J., Sato, A., Akira, S., Medzhitov, R., and Iwasaki, A. 2003. Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J. Exp. Med 198:513-520.
14. Waibler, Z., et al. 2007. Modified vaccinia virus Ankara induces Toll-like receptor-independent type I interferon responses. J. Virol. 81:12102-12110.
15. Engelmayer, J., et al. 1999. Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion. J. Immunol. 163:6762-6768.
16. Drillien, R., Spehner, D., and Hanau, D. 2004. Modified vaccinia virus Ankara induces moderate activation of human dendritic cells. J. Gen. Virol. 85:2167-2175.
17. Naik, S.H., et al. 2005. Cutting edge: generation of splenic CD8+ and CD8- dendritic cell equivalents in Fms-like tyrosine kinase 3 ligand bone marrow cultures. J. Immunol. 174:6592-6597.
18. Muller, U., et al. 1994. Functional role of type I and type II interferons in antiviral defense. Science. 264:1918-1921.
19. Wyatt, L.S., Earl, P.L., Eller, L.A., and Moss, B. 2004. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc. Natl. Acad. Sci. U. S. A. 101:4590-4595.
20. Earl, P.L., et al. 2004. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature. 428:182-185.
21. Stittelaar, K.J., et al. 2005. Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J. Virol. 79:7845-7851.
22. Spies, B., et al. 2003. Vaccination with plasmid DNA activates dendritic cells via Toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice. J. Immunol. 171:5908-5912.
23. Babiuk, S., et al. 2004. TLR9-/- and TLR9+/+ mice display similar immune responses to a DNA vaccine. Immunology. 113:114-120.
24. Mortimer, P.P. 2003. Can postexposure vaccination against smallpox succeed? Clin. Infect. Dis. 36:622-629.
25. Stittelaar, K.J., et al. 2006. Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. Nature. 439:745-748.
26. Staib, C., Suezer, Y., Kisling, S., Kalinke, U., and Sutter, G. 2006. Short-term, but not post-exposure, protection against lethal orthopoxvirus challenge after immunization with modified vaccinia virus Ankara. J. Gen. Virol. 87:2917-2921.
27. Meisinger-Henschel, C., et al. 2007. Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara. J. Gen. Virol. 88:3249-3259.
28. Ishii, K.J., and Akira, S. 2006. Innate immune recognition of, and regulation by, DNA. Trends Immunol 27:525-532.
29. Harte, M.T., et al. 2003. The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense. J. Exp. Med. 197:343-351.
30. Stack, J., et al. 2005. Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence. J. Exp. Med. 201:1007-1018.
31. Parker, A.K., Parker, S., Yokoyama, W.M., Corbett, J.A., and Buller, R.M. 2007. Induction of natural killer cell responses by ectromelia virus controls infection. J. Virol. 81:4070-4079.
32. Chaudhri, G., et al. 2004. Polarized type 1 cytokine response and cell-mediated immunity determine genetic resistance to mousepox. Proc. Natl. Acad. Sci. U. S. A. 101:9057-9062.